Marta Elena Santarone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marta Elena Santarone has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Lucia Fusco
Neurology, Epilepsy, and Movement Disorders Unit Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico Rome Italy
3 shared publications - Stefano Sartori
Department of Women's and Children's Health, University of Padua, Italy; Paediatric Neurology and Neurophysiology Unit, Pediatric Division, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy; Neuroimmunology Group, Paediatric Research Institute "Città della Speranza, Padua, Italy; Department of Neuroscience, University Hospital of Padua, Padua, Italy
2 shared publications - Alberto Verrotti
Department of Pediatrics, University of Perugia, Perugia, Italy
1 shared publication Alessandra Conio
Pediatric Intensive Care Unit Health and Science City Hospital‐University of Turin Turin Italy
1 shared publicationAlessandra Pugi
Clinical Trial Office Meyer Children’s Hospital‐University of Florence Florence Italy
1 shared publication- Alessandro Orsini
Paediatric Neurology, Department of Paediatrics, University Hospital of Pisa, Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 25 July 2022
- Published by Wiley in Epilepsia Open
- Vol. 7 (3) , 532-540
KETASER01 protocol: What went right and what went wrong
Objective: To discuss the results of the KETASER01 trial and the reasons for its failure, particularly in view of future studies.Methods: KETASER01 is a multicenter, randomized, controlled, open‐label, sequentially designed, non‐profit Italian study that aimed to assess the efficacy of ketamine compared with conventional anesthetics in the treatment of refractory convulsive status epilepticus (RCSE) in children.Results: During the 5‐year recruitment phase, a total of 76 RCSEs treated with third‐line therapy were observed in five of the 10 participating Centers; only 10 individuals (five for each study arm; five females, mean age 6.5 ± 6.3 years) were enrolled in the KETASER01 study. Two of the five patients (40%) in the experimental arm were successfully treated with ketamine and two of the five (40%) children in the control arm, where successfully treated with thiopental. In the remaining six (60%) enrolled patients, RCSE was not controlled by the randomized anesthetic(s).Significance: The KETASER01 study was prematurely halted due to low eligibility of patients and no successful recruitment. No conclusions can be drawn regarding the objectives of the study. Here, we discuss the KETASER01 results and critically analyze the reasons for its failure in view of future trials.
- 25 July 2022
- Published by Wiley in Epilepsia Open
- Vol. 7 (3) , 532-540
Open AccessKETASER01 protocol: What went right and what went wrong
Objective: To discuss the results of the KETASER01 trial and the reasons for its failure, particularly in view of future studies.Methods: KETASER01 is a multicenter, randomized, controlled, open‐label, sequentially designed, non‐profit Italian study that aimed to assess the efficacy of ketamine compared with conventional anesthetics in the treatment of refractory convulsive status epilepticus (RCSE) in children.Results: During the 5‐year recruitment phase, a total of 76 RCSEs treated with third‐line therapy were observed in five of the 10 participating Centers; only 10 individuals (five for each study arm; five females, mean age 6.5 ± 6.3 years) were enrolled in the KETASER01 study. Two of the five patients (40%) in the experimental arm were successfully treated with ketamine and two of the five (40%) children in the control arm, where successfully treated with thiopental. In the remaining six (60%) enrolled patients, RCSE was not controlled by the randomized anesthetic(s).Significance: The KETASER01 study was prematurely halted due to low eligibility of patients and no successful recruitment. No conclusions can be drawn regarding the objectives of the study. Here, we discuss the KETASER01 results and critically analyze the reasons for its failure in view of future trials.
- 1 January 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 30, 128-133
Posterior Reversible Encephalopathy Syndrome in infants and young children
- 1 January 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 30, 128-133
Posterior Reversible Encephalopathy Syndrome in infants and young children
- 1 December 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 113, 107531
Three different scenarios for epileptic spasms
- 1 December 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 113, 107531
Three different scenarios for epileptic spasms
- 8 December 2015
- Published by Georg Thieme Verlag KG in Journal of Pediatric Epilepsy
- Vol. 05 (02) , 089-096
Epilepsy Associated with Incontinentia Pigmenti
Incontinentia pigmenti (IP) is an uncommon neurocutaneous syndrome characterized by skin lesions, ocular abnormalities, and central nervous system (CNS) involvement. Mutations in IKBKG gene were discovered as a cause of IP. The most frequent neurologic manifestations are seizures, usually observed in the first week, and sometimes in the first year of life or in childhood. The most frequent types of presenting seizures are partial clonic or generalized seizures. Epilepsy usually showed a good prognosis in most patients with a good response to treatment. However, in some patients a more severe epilepsy related to various degree of CNS involvement can occur. Clinicians should pay special attention to cutaneous signs of IP in infants presenting with neonatal seizures.
- 8 December 2015
- Published by Georg Thieme Verlag KG in Journal of Pediatric Epilepsy
- Vol. 05 (02) , 089-096
Epilepsy Associated with Incontinentia Pigmenti
Incontinentia pigmenti (IP) is an uncommon neurocutaneous syndrome characterized by skin lesions, ocular abnormalities, and central nervous system (CNS) involvement. Mutations in IKBKG gene were discovered as a cause of IP. The most frequent neurologic manifestations are seizures, usually observed in the first week, and sometimes in the first year of life or in childhood. The most frequent types of presenting seizures are partial clonic or generalized seizures. Epilepsy usually showed a good prognosis in most patients with a good response to treatment. However, in some patients a more severe epilepsy related to various degree of CNS involvement can occur. Clinicians should pay special attention to cutaneous signs of IP in infants presenting with neonatal seizures.